User Group Details

Date:  2024-03-07

Time:  12 p.m. EST | 6 p.m. CET

This meeting discusses indication sequencing in the biopharma industry and the application of PrecisionTree to investigate the best clinical trial sequence for a novel drug targeting multiple diseases.

Once a novel molecule is granted patent protection, there is a limited window during which the value of this asset can be maximized. Because of competitive pressures, it is no longer feasible for companies to pursue diseases (or lines of therapy within the same disease) sequentially. Rather, once clinical proof of concept (POC) is established, it is incumbent on companies to make hay while the sun shines and capture as much commercial value under patent protection. In the course of doing so, careful attention must be paid to the degree of risk, level of investment required, and timeline to product launch for each strategic alternative.

With the use of PrecisionTree, this presentation demonstrates how the risk-adjusted net present value of an asset can be affected dramatically by the choice of strategic alternative to pursue multiple diseases sequentially as well as concurrently. Several features of the PrecisionTree are highlighted, including the use of Bayesian revision and sensitivity analysis to highly uncertain parameters.

Lorem ipsum dolor sit amet

Consectetur adipiscing elit, sed do eiusmod tempor incididunt

ut labore et dolore magna aliqua.

Quisque iaculis mi id elementum facilisis.

Morbi at fringilla arcu. Nulla et cursus massa, vel viverra eros. Donec est tortor, iaculis lobortis fringilla eu, tempor sit amet nulla. Vestibulum vestibulum fermentum arcu, non vestibulum libero sagittis eget. Suspendisse porta lacus lorem, vel tincidunt justo fringilla eget.

• Fringilla arcu
• Nulla et cursus massa
• Vel viverra eros

1. Adipiscing elit
2. Eiusmod tempor incididunt
3. Et dolore magna

Consectetur adipiscing elit, sed do eiusmod tempor incididunt